DPS releases 2012 sustainability report
PLANO, Texas — Dr Pepper Snapple Group has released its second full sustainability report, detailing progress toward the company’s five-year environmental and social performance goals initially announced in 2010.
The key accomplishments recorded in the "We Do Good Things with Flavor” report include:
Encouraging active lifestyles and fitness with the launch of Let’s Play, a community partnership to get kids and families active nationwide through a three-year, $15 million grant to KaBoom!;
Recycling 81% of manufacturing waste, exceeding its original goal and putting the company well on the way toward achieving its increased goal of 90% of waste diverted. At the same time, the recycling efforts at just nine DPS sites in 2011 generated $1.3 million in revenue, demonstrating the business value created from such efforts;
Filling 42% of its innovation pipeline in 2011 with projects focused on reduced calories, smaller portion sizes and improved nutrition. This puts the company only 8 percentage points away from reaching its 2015 goal to have half of its innovation projects focused on health and wellness.
Replacing 33,000 out of 60,000 older vending machines and cooling units to be converted by 2015;
Saving $25 million in costs and 31 million lbs. of PET through the light-weighting of packaging since 2007; and
Contributing more than 55,000 volunteer hours to philanthropic activities — more than halfway to its 2015 goal of 100,000 total volunteer hours.
"When we began as an independent, publicly traded company four years ago, we committed to growing our business in a way that delivers shareholder value while also ensuring environmental and social responsibility," DPS president and CEO Larry Young said. "As our business has grown, so have our CSR programs and initiatives. We are proud of the meaningful progress we have made over the past few years and remain dedicated to delivering on our goals."
More information on DPS sustainability goals and initiatives can be found here.
Dr. Reddy’s launches Parkinson’s disease drug
HYDERABAD, India — Dr. Reddy’s Labs has launched a drug for treating Parkinson’s disease, the company said Thursday.
Dr. Reddy’s introduced ropinirole hydrochloride extended-release tablets in the 2-mg, 4-mg, 6-mg, 8-mg and 12-mg strengths. The 2-mg, 4-mg and 6-mg strengths will be available in 30- and 90-count bottle sizes, while the other two strengths will be available in 30-count bottles.
The drug is a generic version of GlaxoSmithKline’s Requip XL, which had sales of $58 million during the 12-month period ended in March, according to IMS Health.
JDRF, BD extend partnership to accelerate development of proprietary glucose-sensing technology
FRANKLIN LAKES, N.J. — A diabetes research organization and a medical technology company have extended their partnership.
The Juvenile Diabetes Research Foundation and medical supply manufacturer BD — which previously collaborated to enhance the use of insulin pumps in patients with Type 1 diabetes — said they will accelerate the development of BD’s proprietary glucose-sensing technology, which has shown promise in providing very accurate and reliable continuous glucose information.
"BD understands and believes in JDRF’s commitment to and excitement about the prospects of developing better technologies in a relatively short timeframe to benefit people with diabetes," JDRF president and CEO Jeffrey Brewer said. "BD is well positioned to address the patient need given its heritage in injection- and infusion-based drug delivery. We look forward to working with BD on this initiative."